Updated SITC data bring NextCure back to earth

While a lack of additional reponses in the latest data from NextCure for NC318 disappointed investors Monday, the results for the SIGLEC15 mAb are still comparable to early monotherapy data for PD-1/PD-L1 inhibitors.

None of the six new patients in the non-small cell lung cancer (NSCLC) cohort of the Phase

Read the full 491 word article

User Sign In